ATE498403T1 - Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren - Google Patents

Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren

Info

Publication number
ATE498403T1
ATE498403T1 AT03741844T AT03741844T ATE498403T1 AT E498403 T1 ATE498403 T1 AT E498403T1 AT 03741844 T AT03741844 T AT 03741844T AT 03741844 T AT03741844 T AT 03741844T AT E498403 T1 ATE498403 T1 AT E498403T1
Authority
AT
Austria
Prior art keywords
nlv
host
norwalk
infection
viruses
Prior art date
Application number
AT03741844T
Other languages
English (en)
Inventor
Xi Jiang
Pendu Jacques Le
Original Assignee
Childrens Hosp Medical Center
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center, Inst Nat Sante Rech Med filed Critical Childrens Hosp Medical Center
Application granted granted Critical
Publication of ATE498403T1 publication Critical patent/ATE498403T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03741844T 2002-05-31 2003-06-02 Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren ATE498403T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38528302P 2002-05-31 2002-05-31
US38529602P 2002-05-31 2002-05-31
PCT/US2003/017247 WO2003101176A2 (en) 2002-05-31 2003-06-02 Method, composition and kit for antigenic binding of norwalk-like viruses

Publications (1)

Publication Number Publication Date
ATE498403T1 true ATE498403T1 (de) 2011-03-15

Family

ID=29715363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741844T ATE498403T1 (de) 2002-05-31 2003-06-02 Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren

Country Status (9)

Country Link
US (3) US20060057562A1 (de)
EP (1) EP1532279B1 (de)
AT (1) ATE498403T1 (de)
AU (2) AU2003273206B2 (de)
CA (1) CA2487846C (de)
DE (1) DE60336063D1 (de)
DK (1) DK1532279T3 (de)
IL (1) IL165486A0 (de)
WO (1) WO2003101176A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) * 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
RU2300826C2 (ru) * 2005-08-05 2007-06-10 Василий Иванович Швейкин Инжекционный излучатель
JP5894528B2 (ja) 2009-06-09 2016-03-30 チルドレンズ ホスピタル メディカル センター 抗原−ノロウイルスｐドメインモノマーおよびダイマー、抗原−ノロウイルスｐ粒子分子、ならびにそれらの製造および使用法
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
WO2018182983A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
EP4589299A3 (de) * 2022-10-18 2025-11-05 Tianjin Dexiang Biotechnology Co., Ltd. Verwendung eines blutgruppenantigen-trisaccharid-konjugats beim nachweis von blutgruppenantikörpern
CN115343485B (zh) * 2022-10-18 2023-01-06 天津德祥生物技术股份有限公司 血型抗原三糖偶联物在血型抗体检测中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5338689A (en) * 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
AU6643290A (en) * 1989-11-08 1991-06-13 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
CA2029219A1 (en) * 1989-11-08 1991-05-09 Mary K. Estes Methods and reagents to detect and characterize norwalk and related viruses
FR2677767B1 (fr) * 1991-06-11 1994-10-14 Biotechnologie Ste Europeenne Procede de detection de l'infection par le virus de la diarrhee bovine, sequence nucleotidique codant pour une proteine induite par l'infection par ce virus et proteines et antigenes recombinants s'y rapportant .
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993019660A1 (en) * 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
US5374532A (en) * 1992-08-31 1994-12-20 The Biomembrane Institute Method for determining susceptibility to escherichia coli urinary tract infections and method for diagnosing secretors and nonsecretors
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
EP0845995A1 (de) * 1995-08-18 1998-06-10 Dr. Rentschler Biotechnologie GmbH Pharmazeutische zusammensetzungen zur kompetitiven inhibition der bindung eines retrovirus an der inf-rezeptor, und mittel für die diagnose von hiv-infektionen
KR970016372U (ko) * 1995-10-04 1997-05-23 음식물 쓰레기 처리장치
US5891862A (en) * 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
EP2263465A1 (de) * 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalente Konjugatvakzine gegen Krebs
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
US7443123B2 (en) * 2004-10-21 2008-10-28 Shop Vac Corporation Method and apparatus for preventing overheating in an electronically commutated motor assembly

Also Published As

Publication number Publication date
US8026221B2 (en) 2011-09-27
IL165486A0 (en) 2006-01-15
US20080274984A1 (en) 2008-11-06
EP1532279A4 (de) 2005-11-09
WO2003101176A8 (en) 2005-11-10
DK1532279T3 (da) 2011-05-23
AU2003273206A1 (en) 2003-12-19
CA2487846C (en) 2012-05-29
US20120071436A1 (en) 2012-03-22
WO2003101176A3 (en) 2005-03-24
EP1532279B1 (de) 2011-02-16
CA2487846A1 (en) 2003-12-11
US20060057562A1 (en) 2006-03-16
DE60336063D1 (de) 2011-03-31
WO2003101176A2 (en) 2003-12-11
AU2009238339A1 (en) 2009-12-10
AU2009238339B2 (en) 2011-06-30
EP1532279A2 (de) 2005-05-25
AU2003273206B2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
SE0301882D0 (sv) New use I
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
ATE470676T1 (de) Anti-vegf-2 antikörper
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ATE429233T1 (de) Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
EP2027874A3 (de) Verfahren zur Verabreichung/Dosierung von Anti-SV-Antikörper zur Prophylaxe und Behandlung
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60336063D1 (de) Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
SE0201940D0 (sv) New combination II
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
SE0401631L (sv) Ny sammansättning
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
EA200100515A2 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
SE0301883D0 (sv) New use II
DE60042489D1 (de) Impfstoff gegen neisseria infektion
SE0301885D0 (sv) New use IV

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties